Prevalence of antibody positivity to SARS-CoV-2 following the first peak of infection in England: serial cross-sectional studies of 365,000 adults

Ward, H; Cooke, GS; Atchison, C; Whitaker, M; Elliott, J; Moshe, M; Browne, JC; Flower, B; Daunt, A; Ainslie, K; Ashby, D; Donnelly, CA; Riley, S; Darzi, A; Barclay, W; Elliott, P

Journal article

Prevalence of antibody positivity to SARS-CoV-2 following the first peak of infection in England: serial cross-sectional studies of 365,000 adults

Abstract:: Background
The time-concentrated nature of the first wave of the COVID-19 epidemic in England in March and April 2020 provides a natural experiment to measure changes in antibody positivity at the population level before onset of the second wave and initiation of the vaccination programme.
Methods
Three cross-sectional national surveys with non-overlapping random samples of the population in England undertaken between late June and September 2020 (REACT-2 study). 365,104 adults completed questionnaires and self-administered lateral flow immunoassay (LFIA) tests for IgG against SARS-CoV-2.
Findings
Overall, 17,576 people had detectable antibodies, a prevalence of 4.9% (95% confidence intervals 4.9, 5.0) when adjusted for test characteristics and weighted to the adult population of England. The prevalence declined from 6.0% (5.8, 6.1), to 4.8% (4.7, 5.0) and 4.4% (4.3, 4.5), over the three rounds of the study a difference of -26.5% (-29.0, -23.8). The highest prevalence and smallest overall decline in positivity was in the youngest age group (18-24 years) at -14.9% (-21.6, -8.1), and lowest prevalence and largest decline in the oldest group (>74 years) at -39.0% (-50.8, -27.2). The decline from June to September 2020 was largest in those who did not report a history of COVID-19 at -64.0% (-75.6, -52.3), compared to -22.3% (-27.0, -17.7) in those with SARS-CoV-2 infection confirmed on PCR.
Interpretation
A large proportion of the population remained susceptible to SARS-CoV-2 infection in England based on naturally acquired immunity from the first wave. Widespread vaccination is needed to confer immunity and control the epidemic at population level.
Funding
This work was funded by the Department of Health and Social Care in England.

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Cite

Cite this record

APA Style

Ward, H., Cooke, G. S., Atchison, C., Whitaker, M., Elliott, J., Moshe, M., Browne, J. C., Flower, B., Daunt, A., Ainslie, K., Ashby, D., Donnelly, C. A., Riley, S., Darzi, A., Barclay, W., & Elliott, P. (2021). Prevalence of antibody positivity to SARS-CoV-2 following the first peak of infection in England: serial cross-sectional studies of 365,000 adults. Lancet Regional Health - Europe, 4.

MLA Style

Ward, H., et al. “Prevalence of Antibody Positivity to SARS-CoV-2 Following the First Peak of Infection in England: Serial Cross-Sectional Studies of 365,000 Adults.” Lancet Regional Health - Europe, vol. 4, Elsevier, 2021.

Chicago Style

Ward, H, GS Cooke, C Atchison, M Whitaker, J Elliott, M Moshe, JC Browne, et al. 2021. “Prevalence of Antibody Positivity to SARS-CoV-2 Following the First Peak of Infection in England: Serial Cross-Sectional Studies of 365,000 Adults.” Lancet Regional Health - Europe 4.
Share
Print